Metastatic Breast Cancer Clinical Trials

950 clinical trials for Metastatic Breast Cancer across international registries, including 146 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer — RECRUITING · PHASE1
• Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer — RECRUITING · PHASE2
• Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC — RECRUITING · PHASE2
• A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer — RECRUITING
• Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer — RECRUITING · PHASE2
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread — RECRUITING · PHASE1
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors — RECRUITING · PHASE1
• Generative AI Patient Education Module for Breast Oncology — RECRUITING · NA
• AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. — RECRUITING · NA
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — RECRUITING · PHASE3
• Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment — RECRUITING · PHASE3
• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies — RECRUITING · PHASE2
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer — RECRUITING · PHASE2
• A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer — RECRUITING · PHASE3
• Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling. — RECRUITING
• A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. — RECRUITING · PHASE2
• A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer — RECRUITING · PHASE1
• PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer — RECRUITING · PHASE1
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer — RECRUITING · PHASE3
• Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers — RECRUITING · PHASE4
• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure — RECRUITING · PHASE1
• Fast-Her: Fasting Effects on Breast Cancer Treatment — RECRUITING · NA
• A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer — RECRUITING · PHASE2
• A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer — RECRUITING · PHASE1
• Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis — RECRUITING · PHASE2
• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer — RECRUITING · PHASE2
• Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry) — RECRUITING
• DESTINY Breast Respond HER2-(Ultra)Low Europe — RECRUITING
• The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study — RECRUITING · PHASE3
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors — RECRUITING · PHASE1
• BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer — RECRUITING · PHASE1
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation — RECRUITING · PHASE3
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer — RECRUITING · PHASE1
• Scalp Cooling in MBC — RECRUITING · PHASE2
• CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer — RECRUITING · PHASE1
• Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy — RECRUITING
• PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) — RECRUITING · PHASE2
• First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer — RECRUITING · PHASE1
• ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer — RECRUITING · PHASE1
• Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) — RECRUITING · PHASE2
• HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011 — RECRUITING · PHASE2
• A Study of HLD-0117 in Patients With Metastatic Breast Cancer — RECRUITING · PHASE1
• DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients — RECRUITING
• A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer — RECRUITING · PHASE1
• Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer — RECRUITING · NA
• Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 — RECRUITING
• Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns — RECRUITING
• A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers. — RECRUITING · PHASE1

Refine this search